{
    "Trade/Device Name(s)": [
        "Simplexa COVID-19 Direct",
        "Simplexa\u2122 COVID-19 Direct"
    ],
    "Submitter Information": "DiaSorin Molecular LLC",
    "510(k) Number": "K212147",
    "Predicate Device Reference 510(k) Number(s)": [
        "K211079"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QQX",
        "OOI"
    ],
    "Summary Letter Date": "August 12, 2022",
    "Summary Letter Received Date": "August 15, 2022",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3981",
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Device to detect and identify nucleic acid targets in respiratory specimens from microbial agents that cause the SARS-CoV-2 respiratory infection and other microbial agents when in a multi-target test",
        "Instrumentation for clinical multiplex test systems"
    ],
    "Analyte Class(es)": [
        "virology",
        "genetic molecular",
        "microbiology"
    ],
    "Analyte(s)": [
        "SARS-CoV-2 RNA",
        "ORF1ab gene",
        "S gene"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Nasal swab"
    ],
    "Specimen Container(s)": [
        "Universal Transport Media (UTM)",
        "Primary collection tubes"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON MDX instrument",
        "LIAISON MDX Studio Software"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time RT-PCR",
        "Direct amplification"
    ],
    "Methodologies": [
        "RT-PCR",
        "Molecular detection",
        "Qualitative nucleic acid amplification"
    ],
    "Submission Type(s)": [
        "Assay",
        "System",
        "Reagent",
        "Accessory",
        "Component",
        "Disc",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin Molecular Simplexa COVID-19 Direct real-time RT-PCR assay for SARS-CoV-2 qualitative detection on LIAISON MDX instrument",
    "Indications for Use Summary": "Qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal and nasal swab specimens from symptomatic individuals suspected of COVID-19 by healthcare providers, as an aid in the diagnosis of SARS-CoV-2 infection",
    "fda_folder": "Microbiology"
}